Beth Adamson, Nicholas Brittain, Laura Walker, Ruaridh Duncan, Sara Luzzi, Pasquale Rescigno, Graham Smith, Suzanne McGill, Richard Js Burchmore, Elaine Willmore, Ian Hickson, Craig N Robson, Denisa Bogdan, Juan M Jimenez-Vacas, Alec Paschalis, Jonathan Welti, Wei Yuan, Stuart R McCracken, Rakesh Heer, Adam Sharp, Johann S de Bono, Luke Gaughan
Aberrant androgen receptor (AR) signaling drives prostate cancer (PC), and it is a key therapeutic target. Although initially effective, the generation of alternatively spliced AR variants (AR-Vs) compromises efficacy of treatments. In contrast to full-length AR (AR-FL), AR-Vs constitutively activate androgenic signaling and are refractory to the current repertoire of AR-targeting therapies, which together drive disease progression. There is an unmet clinical need, therefore, to develop more durable PC therapies that can attenuate AR-V function...
November 15, 2023: Journal of Clinical Investigation